Fidelity Biosciences
VC Fund
Fidelity Biosciences is a VC fund focused on Health Care and Biotechnology. Fidelity Biosciences
- Total investments:
- 4
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Fidelity Biosciences invests in
Stages Fidelity Biosciences invests in
Countries Fidelity Biosciences invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Jon Lim
|
|||
Investment Focus
Industry
- Health Care 3 (75%)
- Biotechnology 3 (75%)
- Pharmaceutical 2 (50%)
- Medical 1 (25%)
- Bioinformatics 1 (25%)
Stage
- Series B 2 (50%)
- Series C 1 (25%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Jon Lim
Partner
|
Partner | Total investments: 18 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Blueprint Medicines
|
Blueprint Medicines develops targeted therapies for cancer and blood disorders, focusing on precision medicine. The company utilizes genetic insights to design treatments tailored to individual patient needs. Their portfolio includes products aimed at specific mutations and conditions, enhancing treatment options for patients with various types ofcancer and hematologic diseases. Blueprint Medicines collaborates with healthcare providers to ensure that their therapies are accessible and effectively integrated into patient care. Through ongoing research and development, the company aims to expand its offerings and address unmet medical needs in oncology and hematology. | $50M / Series C / Nov 12, 2014 | |
NeuroTherapeutics Pharma
|
NeuroTherapeutics Pharma, Inc., a biopharmaceutical company, develops therapeutics for patients suffering from central nervous system disorders. It focuses on epilepsy, neuropathic, and acute pain disorders of the nervous system. The company was incorporated in 2006 and is based in Chicago, Illinois. | Series B / May 20, 2010 | |
Cardiokine
|
Cardiokine, Inc., a specialty pharmaceutical company, engages in the development of pharmaceuticals for the prevention and treatment of cardiovascular diseases. Its products include lixivaptan, an orally active vasopressin receptor antagonist for patients with congestive heart failure who suffer from hyponatremia. The company was founded in 2004and is headquartered in Philadelphia, Pennsylvania. | $50M / Series B / May 01, 2006 | |
Kyruus Health
|
Kyruus Health is a care access platform that provides solutions for providers data management, patient engagement, and activation. | Series C |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Fidelity Biosciences invest in?
Fidelity Biosciences invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series B and Series C stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Fidelity Biosciences?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Fidelity Biosciences?
The team at Fidelity Biosciences includes Jon Lim (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
